The University of Texas MD Anderson Cancer Center and The University of Texas Health Science Center at Houston (UTHealth Houston) today announced Alejandro Aballay, PharmD, PhD, a national leader in immune signaling and graduate education, has been named dean of the MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, effective Jan. 2, 2024.
The graduate school, jointly operated by UTHealth Houston and MD Anderson, trains the next generation of biomedical scientists to conduct groundbreaking research that addresses health care’s most pressing needs. Under the school’s umbrella program, students seeking master’s and doctoral degrees gain the opportunity to work with more than 600 faculty from both institutions, including some of the world’s leading experts across a variety of scientific disciplines.
“Dr. Aballay is a consummate scientist with a vision for enhancing the graduate school’s national standing and global presence,” said Giuseppe N. Colasurdo, MD., president of UTHealth Houston and the Alkek-Williams Distinguished Chair at the university. “As the graduate school celebrates its 60th anniversary this year, we look forward to Dr. Aballay leading us toward an exciting future.”
Currently, Aballay serves as professor and chair of the Department of Molecular Microbiology and Immunology at Oregon Health & Science University (OHSU) in Portland. He joined OHSU in 2017 and in his six years as chair, Aballay focused on faculty recruitment, mentoring, and retention, as well as intradepartmental collaboration and a major building renovation to enhance laboratory space. He also led the department’s response during the COVID-19 pandemic, quickly building a biosafety Level 2 Plus (BSL-2+) lab to facilitate grant applications to study the new virus.
“Educating and training the next generation of cancer scientists is critical to advancing our mission to end cancer. After a competitive national search, we are pleased to welcome Dr. Aballay as dean of our graduate school,” said Peter WT Pisters, MD, president of MD Anderson. “Dr. Aballay will work with interprofessional teams to ensure the graduate school’s programs continue to align with the evolving competencies students need to advance scientific discovery and health technologies in the coming decades.”
Aballay has a broad research program encompassing genetics, functional genomics and neurobiological approaches to study mechanisms involved in the neural control of immune responses and cellular homeostatic mechanisms. Given his research expertise, Aballay will be appointed professor in the Department of Genetics at MD Anderson, with a joint appointment in the Department of Microbiology and Molecular Genetics at McGovern Medical School at UTHealth Houston.
During his graduate studies, Aballay developed an interest in bacterial physiology and regulation while studying the intracellular transport of the bacterial pathogen Brucella abortus. He earned a doctorate in molecular and cell biology from the Nacional de Cuyo University Medical School and a doctorate in pharmacology from Juan Agustín Maza University in Mendoza, Argentina. He also studied cell biology at Washington University in St. Louis during his graduate studies. Following his doctoral work, he completed postdoctoral fellowships in Molecular Pathogenesis at Harvard Medical School and Massachusetts General Hospital, where he developed a novel pathogenesis system using the nematode Caenorhabditis elegans.
His independent academic career began in 2002 as assistant professor of molecular genetics and microbiology at Duke University Medical Center in Durham, North Carolina, where he studied what makes bacteria pathogenic and how hosts become resistant to infection. Rising through the academic ranks, he was appointed associate professor in 2009 and professor in 2016. He served as director of Duke’s Center for Host-Microbial Interactions from 2014 to 2017.
“I am proud to be joining these stellar institutions and, together, working to educate some of the top minds in the world,” Aballay said. “Our future is bright and full of new opportunities to foster collaboration in interprofessional teams to expand our horizons and strengthen graduate education.”
Aballay has long been committed to education, creating a robust training environment for graduate students, postdoctoral fellows, medical students, and medical fellows. In addition to mentoring undergraduate and graduate students, he has served as training grant director and as a member of the executive, advisory, and admissions committees in four graduate programs. He was also a thesis committee member for graduate students at Duke.
Aballay will work closely with members of the leadership team at MD Anderson UTHealth Houston Graduate School, including Sharon Dent, PhD, chair of Epigenetics and Molecular Carcinogenesis at MD Anderson, who has served as dean ad interim since 2022.
About UTHealth Houston
Established in 1972 by The University of Texas System Board of Regents, The University of Texas Health Science Center at Houston (UTHealth Houston) is Texas’ resource for health care education, innovation, scientific discovery, and excellence in patient care. The most comprehensive academic health center in the UT System and the U.S. Gulf Coast region, UTHealth Houston is home to Jane and Robert Cizik School of Nursing, John P. and Kathrine G. McGovern Medical School, D. Bradley McWilliams School of Biomedical Informatics, and schools of biomedical sciences, dentistry, and public health. UTHealth Houston includes the John S. Dunn Behavioral Sciences Center and UTHealth Houston Harris County Psychiatric Center, as well as the clinical practices UT Physicians, UT Dentists, and UT Health Services. The university’s primary teaching hospitals are Memorial Hermann-Texas Medical Center, Children’s Memorial Hermann Hospital, and Harris Health Lyndon B. Johnson Hospital. For more information, visit UTH.edu.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education, and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
Media Inquiries: 713-500-3030